Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
A Clinical Trial of Non-cationic Peptide-CD47 siRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Male or female patients aged ≥18 years and ≤70 years.
- Histopathologically confirmed advanced recurrent/metastatic malignant solid tumors that are refractory to second-line treatment and have no available standard clinical therapeutic options (e.g., advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.).
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- Expected overall survival ≥3 months.
- Interval from the last chemotherapy, radiotherapy, or surgery ≥28 days.
- Interval from the last use of nitrosourea or mitomycin C ≥6 weeks.
- Adequate organ function, defined by the following laboratory parameters within 14 days prior to enrollment:
- Hemoglobin ≥90 g/L (no blood transfusion within 14 days).
- Absolute neutrophil count >1.5 × 10⁹/L.
- Platelet count ≥80 × 10⁹/L.
- Total bilirubin ≤1.5 × upper limit of normal (ULN).
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN in case of liver metastasis).
- Creatinine clearance ≥60 mL/min (calculated by Cockcroft-Gault formula).
- Left ventricular ejection fraction (LVEF) ≥50%.
- Signed written informed consent.
Exclusion Criteria:
- Participation in another investigational drug clinical trial within 4 weeks.
- Tumor located adjacent to major blood vessels or trachea.
- Uncontrolled cardiac clinical symptoms or diseases, including New York Heart -Association (NYHA) Class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular/ventricular arrhythmias requiring treatment or intervention.
- Female patients who are pregnant or lactating.
- Active pulmonary tuberculosis, bacterial or fungal infection (≥Grade 2 per NCI-CTCAE version 5.0), active human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection.
- History of uncontrollable psychoactive substance abuse or presence of mental disorders.
- Any active autoimmune disease or history of autoimmune disease, including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism. Subjects with vitiligo or childhood asthma in complete remission (no adult intervention required) are eligible; subjects with asthma requiring bronchodilator therapy are excluded.
- Receiving immunosuppressive therapy.
- History of drug abuse or known medical, psychological, or social conditions that interfere with study compliance (e.g., alcoholism or illicit drug addiction).
- Known hypersensitivity, allergy, or intolerance to the study drug NCP-CD47 siRNA (including any excipients), or history of severe allergic reactions to any drugs, foods, or vaccines (e.g., anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local Arthus reaction, etc.).
- Female subjects planning pregnancy, or male subjects whose partner plans pregnancy, from screening until 12 months after the last study drug injection.
- Any concomitant disease that, in the investigator's judgment, may seriously compromise patient safety or prevent the subject from completing the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Intratumoral NCP-CD47 siRNA injection group
|
NCP-CD47 siRNA will be administered via intratumoral injection.
A total of 5 doses will be given, with subsequent doses administered once weekly after the first injection.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Tidsramme: From the first dose to the end of treatment at 9 weeks
|
DLT is defined as any Treatment-Related Adverse Event (TRAE) or clinically significant laboratory abnormality occurring during the DLT observation period.
TRAEs include events judged by the investigator to be "definitely," "probably," or "possibly" related to the study treatment.
Severity will be graded according to NCI-CTCAE v5.0.
|
From the first dose to the end of treatment at 9 weeks
|
|
Number of participants with treatment discontinuation due to treatment-related adverse events during the first treatment cycle
Tidsramme: From the first dose to the end of treatment at 9 weeks
|
Treatment-related adverse events (TRAEs) will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Treatment discontinuation is defined as permanent cessation of NCP-CD47 siRNA administration due to investigator-determined TRAEs occurring during the first treatment cycle.
|
From the first dose to the end of treatment at 9 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival
Tidsramme: Up to 6 months from the date of the first dose.
|
Progression-Free Survival (PFS) is defined as the time interval from the start of treatment until the first documented occurrence of disease progression (PD) according to RECIST v1.1, or death due to any cause, whichever occurs first.
|
Up to 6 months from the date of the first dose.
|
|
Overall Survival
Tidsramme: Up to 12 months from the date of the first dose.
|
OS is defined as the time interval from the start of treatment to death due to any cause.
For participants who are still alive at the end of the study, data will be censored at the last known date of follow-up.
|
Up to 12 months from the date of the first dose.
|
|
Objective Response
Tidsramme: Time Frame: Up to 6 months from the date of the first dose.
|
Number of participants achieving a Best Overall Response (BOR) of either Complete Response (CR) or Partial Response (PR) according to RECIST v1.1.
Due to the small sample size, data will be reported as absolute counts.
|
Time Frame: Up to 6 months from the date of the first dose.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2026-892
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .